Skip to main content

Helene Peyro-Saint-Paul, Pascale Beurdeley, and Jean-Marie Charpin

PathoQuest has announced an expansion of its executive team by appointing Helene Peyro-Saint-Paul as chief medical officer, Pascale Beurdeley as CSO, and Jean-Marie Charpin as global commercial head of viral safety.

In her role as CMO, Peyro-Saint-Paul will be in charge of medical affairs, development strategy, and market access. Most recently, Peyro-Saint-Paul served as CMO at Qiagen Marseille, formerly Ipsogen, and HalioDx, a company she co-founded. In her role as CSO, Beurdeley will lead PathoQuest's research and development activities while providing insight and expertise on all the scientific aspects of the company's technology. Most recently Beurdeley held several positions at DiaxonHit, formerly ExonHit Therapeutics, where she contributed to the development and promotion of the company's proprietary platform for the analysis of gene expression and alternative splicing. In his role as commercial head of viral safety, Charpin will drive commercial efforts associated with PathoQuest's viral safety testing business. Most recently, he served as business account manager and product manager at OncoDesign, where he developed the business in north Europe and successfully launched innovative services for preclinical oncology worldwide.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.